in clinical trials
Weight Management
Your weight isn’t a willpower problem. It’s biology.
Medically-supervised treatment with the latest GLP-1 medications, prescribed by our GPs and delivered to your door.
Weight gain has many causes.
None of them are your fault.
Genetics
Over 200 genes influence body weight and fat distribution
Hormones
Appetite hormones can override your best intentions
Metabolism
Your body actively resists weight loss after dieting
Evidence-Based
The science behind lasting results
Mounjaro
tirzepatide
Dual GIP + GLP-1 receptor agonist
Up to 22.5% body weight loss in trials1
- Reduces appetite and food cravings
- Improves blood sugar regulation
- Once-weekly self-injection
- Gradual dose escalation over 20 weeks
- Most common side effects are mild GI symptoms
Wegovy
semaglutide
GLP-1 receptor agonist
Up to 15% body weight loss in trials2
- Signals fullness to the brain
- Shown cardiovascular benefits
- Once-weekly self-injection
- Dose titration over 16 weeks
- Well-established safety profile since 2021
Your Journey
Three steps. That’s it.
Online consultation
15 minutes, from home. Share your history and goals.
GP prescribes
Reviewed by our doctors. Bloods taken at our clinic if needed.
Medication delivered
Monthly, to your door. Ongoing GP support included.
Results
What to expect
Month 1
Appetite changes
Reduced cravings, feeling fuller sooner. Typical loss: 2\u20135% body weight.
Months 2\u20133
Steady progress
Consistent weight loss as dosage optimises. Typical loss: 5\u201310% total.
Months 6\u201312
New baseline
Significant transformation. Typical loss: 15\u201320% total body weight.
Investment
Transparent pricing. No hidden fees.
Monthly price includes medication, GP consultations, and blood monitoring. Dose-specific pricing discussed at your consultation.
Am I suitable?
- BMI of 30 or above
- BMI of 27+ with a weight-related condition (e.g. type 2 diabetes, high blood pressure, sleep apnoea)
- Age 18 or over
- Previous attempts at lifestyle changes alone haven’t worked
May not be suitable if:
Pregnant or planning pregnancy · Personal or family history of medullary thyroid carcinoma or MEN2 syndrome · Type 1 diabetes · History of pancreatitis · Severe gastrointestinal disease. Our GPs will assess your full medical history during consultation.
Common questions
Ready to start?
Or call us: 01676 545 111
1 SURMOUNT-1 trial: Jastreboff AM, et al. N Engl J Med. 2022;387:205-216. Tirzepatide for obesity.
2 STEP 1 trial: Wilding JPH, et al. N Engl J Med. 2021;384:989-1002. Semaglutide for obesity.
Individual results may vary. All treatments prescribed by GMC-registered GPs.